These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 21167517)

  • 1. Paclitaxel-hyaluronic acid for intravesical therapy of bacillus Calmette-Guérin refractory carcinoma in situ of the bladder: results of a phase I study.
    Bassi PF; Volpe A; D'Agostino D; Palermo G; Renier D; Franchini S; Rosato A; Racioppi M
    J Urol; 2011 Feb; 185(2):445-9. PubMed ID: 21167517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (30993).
    Oosterlinck W; Kirkali Z; Sylvester R; da Silva FC; Busch C; Algaba F; Collette S; Bono A
    Eur Urol; 2011 Mar; 59(3):438-46. PubMed ID: 21156335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravesical instillations with bacillus calmette-guérin for the treatment of carcinoma in situ involving prostatic ducts.
    Palou Redorta J; Schatteman P; Huguet Pérez J; Segarra Tomás J; Rosales Bordes A; Algaba F; Villavicencio Mavrich H
    Eur Urol; 2006 May; 49(5):834-8; discussion 838. PubMed ID: 16426729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients.
    Yossepowitch O; Eggener SE; Bochner BH; Donat SM; Herr HW; Dalbagni G
    J Urol; 2006 Aug; 176(2):482-5. PubMed ID: 16813873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation.
    Takayama H; Nishimura K; Tsujimura A; Nakai Y; Nakayama M; Aozasa K; Okuyama A; Nonomura N
    J Urol; 2009 Apr; 181(4):1894-900. PubMed ID: 19237175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintenance intravesical bacillus Calmette-Guérin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: randomized controlled trial by the BCG Tokyo Strain Study Group.
    Koga H; Ozono S; Tsushima T; Tomita K; Horiguchi Y; Usami M; Hirao Y; Akaza H; Naito S;
    Int J Urol; 2010 Sep; 17(9):759-66. PubMed ID: 20604814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder.
    Berglund RK; Savage CJ; Vora KC; Kurta JM; Cronin AM
    J Urol; 2008 Oct; 180(4):1297-300; discussion 1300. PubMed ID: 18707737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
    Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
    J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
    Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
    Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ: relationship of progression to histological response and p53 nuclear accumulation.
    Ovesen H; Horn T; Steven K
    J Urol; 1997 May; 157(5):1655-9. PubMed ID: 9112499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The case for conservative management in the treatment of patients with non-muscle-invasive micropapillary bladder carcinoma without carcinoma in situ.
    Gaya JM; Palou J; Algaba F; Arce J; Rodríguez-Faba O; Villavicencio H
    Can J Urol; 2010 Oct; 17(5):5370-6. PubMed ID: 20974029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 2-week maintenance regimen of intravesical instillation of bacillus Calmette-Guerin is safe, adherent and effective in patients with non-muscle-invasive bladder cancer: a prospective, multicenter phase II clinical trial.
    Kanagawa Urological Research Group (KURG)
    Jpn J Clin Oncol; 2012 Sep; 42(9):813-9. PubMed ID: 22761255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ of bladder].
    Uekado Y; Kohjimoto Y; Iba A; Kikkawa K; Shintani Y; Shinka T
    Hinyokika Kiyo; 2006 Jun; 52(6):439-44. PubMed ID: 16848357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder.
    Kim JC; Steinberg GD
    J Urol; 2001 Mar; 165(3):745-56. PubMed ID: 11176460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Editorial comment to Maintenance intravesical bacillus Calmette-Guérin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: randomized controlled trial by the BCG Tokyo Strain Study Group.
    Mostafid H
    Int J Urol; 2010 Sep; 17(9):766-7. PubMed ID: 20727047
    [No Abstract]   [Full Text] [Related]  

  • 17. The effect of intravesical instillation of antifibrinolytic agents on bacillus Calmette-Guerin treatment of superficial bladder cancer: a pilot study.
    Pan CW; Shen ZJ; Ding GQ
    J Urol; 2008 Apr; 179(4):1307-11; discussion 1311-2. PubMed ID: 18289576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Intravesical Bacillus Calmette-Guerin (BCG: Tokyo 172 strain) instillation for carcinoma in situ of the bladder: results with 6 successive instillations of 40 mg BCG].
    Mugiya S; Nagata M; Takayama T; Ozono S; Ito T; Maruyama S; Hadano S; Nagae H
    Hinyokika Kiyo; 2004 Jul; 50(7):469-73. PubMed ID: 15334890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of bacillus Calmette-Guérin refractory nonmuscle invasive bladder cancer.
    McKiernan JM; Barlow LJ; Laudano MA; Mann MJ; Petrylak DP; Benson MC
    J Urol; 2011 Aug; 186(2):448-51. PubMed ID: 21680003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.